Skip to content
mapperlab
← Dashboard
Stock

PBH

PRESTIGE CONSUMER HEALTHCARE INC.
Health CarePharmaceuticalsLatest close $476 of 27 marquee funds currently hold1 CUSIP mapped
Current holders
6
27 funds tracked
Ever held
9
Current + past
New this quarter
1
Exited this quarter
0

Marquee-fund ownership over time

Aug 14, 2019Nov 15, 2021Aug 14, 2024May 15, 2026
Now
6

This quarter's activity

New positions opened

Positions exited

None.

Current holders

Sorted by tenure (longest first)
FundEntry priceLatest closeReturn on entry
Renaissance Technologies$66$47-30%
Citadel Advisors re-entered$67$47-31%
Two Sigma Investments re-entered$67$47-31%
D.E. Shaw$67$47-31%
AQR Capital Management$67$47-31%
Millennium Management$67$47-31%

“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.

Past holders

Funds that exited at some point
FundEntry → ExitReturn
Bridgewater Associates→ $67+11%
Maverick Capital 4× in & out→ $68+19%
Coatue Management→ $38+17%

Insider activity

Form 4 — officers, directors, 10%+ owners

Filed within two business days of each transaction by anyone with material insider status at Prestige Consumer Healthcare Inc.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.

Filings · last 30d
19
Filings · last 90d
20
Total on file
511
Recent SEC buffer
Most recent
May 14, 2026

30d / 90d windows measured from May 14, 2026 — the most recent Form 4 on file — not from today.

Showing 15 of 511 recent Form 4 filings. Browse all on EDGAR ↗

Fundamentals

XBRL · PRESTIGE CONSUMER HEALTHCARE INC.

Annual figures sourced directly from PRESTIGE CONSUMER HEALTHCARE INC.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.

Revenue
$1.09B
FY2026-4% YoY
Net income
$190.3M
FY2026-11% YoY
EPS (diluted)
$3.91
FY2026-9% YoY
Free cash flow(?)
$246.45M
FY2026+1% YoY

Recent SEC filings

10-K · 10-Q · 8-K · 13D/G · proxy

The most recent material filings for Prestige Consumer Healthcare Inc. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.

Trade history

Every open→close lifecycle across tracked funds
FundOpen dateClose dateOpen priceClose price / currentReturn
Two Sigma InvestmentsQ2 2026open$47$47-0%
Citadel AdvisorsQ4 2025open$60$47-22%
Bridgewater AssociatesQ4 2025Q1 2026$60$67+11%
Citadel AdvisorsQ3 2024Q3 2025$67$65-4%
Two Sigma InvestmentsQ3 2024Q4 2025$67$60-11%
D.E. ShawQ3 2024open$67$47-31%
AQR Capital ManagementQ3 2024open$67$47-31%
Millennium ManagementQ3 2024open$67$47-31%
Renaissance TechnologiesQ3 2024open$66$47-30%
Maverick CapitalQ2 2022Q1 2024$57$68+19%
Maverick CapitalQ4 2021Q1 2022$61$58-5%
Maverick CapitalQ2 2020Q3 2020$40$38-5%
Coatue ManagementQ3 2019Q4 2019$32$38+17%
Maverick CapitalQ3 2019Q1 2020$32$42+31%
Caveats
  • Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
  • Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
  • “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
  • Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
  • Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.